As part of our effort to improve access to affordable healthcare, our Pharmacy department is reducing administrative burden by extending the approved date range for certain maintenance medications. We began this update process on December 23, 2025.
Active authorizations for the below medications were extended by five years for commercial members and one year for Medicaid members.
Please verify authorization dates in the InTouch for Providers portal.
Prescription benefit drugs
Cosentyx, Cimzia, Enbrel, Orencia, Otezla, Rinvoq, Skyrizi, Dupixent, Fasenra, Nucala, Tezspire, Xolair
Adalimumab Biosimilars: Adalimumab-ADAZ, Adalimumab-FKJP, Hadlima, Hyrimoz
Ustekinumab Biosimilars: Selarsdi, Yesintek
Briviact, Epidiolex, Pulmozyme, Trikafta, Winrevair, Sildenafil 20mg oral tablet (PAH), Tadalafil 20mg oral tablet (PAH)
Non-Preferred Test Strips
Medical benefit drugs
Botox, Dysport, Xeomin, Eylea, Eylea HD, Vabysmo, Vyepti
Infliximab Biosimilars: Avsola, Inflectra, Renflexis
Tocilizumab Biosimilars: Tofidence, Tyenne
Benlysta, Saphnelo, Fasenra, Nucala, Xolair
Rituximab Biosimilars: Riabni, Ruxience, Truxima